Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

"Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan." Expert Review of Vaccines, 21(5), pp. 591–592

Declaration of interest

A Igarashi has disclosed that he received a consultant fee from Pfizer Japan, Inc., in connection with the conduct of this study. In addition, he has disclosed that he received grants from Taiho Pharmaceutical Co. Ltd., grants and other from Gilead Sciences KK., grants from Intuitive Surgical GK., grants from Boston Scientific Japan Inc., grants and personal fees from Pfizer Japan Inc., grants from Becton Dickinson and Company, grants from Milliman Inc., personal fees and other from Terumo corporation, personal fees from Chugai Pharmaceuticals Inc., personal fees from Astellas Pharma Inc., other from Fuji film Inc., other from CSL Behring Japan Inc., personal fees from Sanofi Japan Inc., personal fees and other from Takeda Pharmaceutical Inc., personal fees from Nippon Boehringer Ingelheim Inc., personal fees from Ono pharmaceutical Inc., personal fees from Novartis Pharma Japan Inc., personal fees from Eisai Inc., personal fees from AbbVie GK, personal fees from Sumitomo Dainippon Pharma Inc., personal fees from Ayumi Pharmaceutical Inc., personal fees from Medilead Inc., personal fees from Novo Nordisk Japan Inc., personal fees from GSK Japan Inc., outside the submitted work. E Hirose, Y Kobayashi, N Yonemoto and B Lee have disclosed that they are employees of Pfizer Japan Inc. and stockholders of Pfizer Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This letter was funded by Pfizer Japan Inc., Tokyo, Japan.